

=> b reg
FILE 'REGISTRY' ENTERED AT 16:29:25 ON 10 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUN 2008 HIGHEST RN 1026855-74-2
DICTIONARY FILE UPDATES: 9 JUN 2008 HIGHEST RN 1026855-74-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta 16
L4 STR




VAR G1=O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 28

STEREO ATTRIBUTES: NONE
L6 599 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED 121210 ITERATIONS 599 ANSWERS
SEARCH TIME: 00.00.04

=> d que sta 110
L4 STR



VAR G1=O/S

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM


DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 28

STEREO ATTRIBUTES: NONE

L6 599 SEA FILE=REGISTRY SSS FUL L4
L8 STR

VAR G1=O/S

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE

L10 170 SEA FILE=REGISTRY SUB=L6 SSS FUL L8

100.0% PROCESSED 599 ITERATIONS
SEARCH TIME: 00.00.01

170 ANSWERS

=> b hcap
FILE 'HCAPLUS' ENTERED AT 16:29:34 ON 10 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Jun 2008 VOL 148 ISS 24
FILE LAST UPDATED: 9 Jun 2008 (20080609/ED)


New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitstr 114 tot


L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:438817 HCAPLUS
 DN 146:433450
 TI Preparation of gallium complexes of N-(carboxymethyl)azamacrocycles linked to biovectors as PET imaging agents
 IN Port, Marc; Corot, Claire; Gautherot, Thierry
 PA Guerbet, Fr.
 SO PCT Int. Appl., 51pp.
 CODEN: PIXXD2
 DP Patent
 LA French
 FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO-2007042504	A2	20070419	2006W0-EP0067211	20061009
WO-2007042504	A3	20080228		
NP: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KR, KG, KM, KN, KP, LV, LZ, MA, ME, MG, MN, MO, NE, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, GM, SV, SY, TZ, TM, TN, TR, TT, TW, UA, US, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, MT, NL, PT, RO, SE, SI, SK, TR, BE, RU, HJ, GM, KE, LI, MN, ME, NA, SD, SL, SZ, TZ, US, ZM, ZW, AM, AZ, BY, RG, KE, MD, RU, TJ, TM, AP, EA, EP, OA				
FR: 2891830	A1	20070413	2005FR-000010289	20051007
EP: 2899556	A1	20071012	2006FR-000002975	20060405
PRAI 2005FR-00000289	A	20051007		
2006FR-000002975	A	20060405		
OS MARPAT 146:433450				
GI				




AB The invention concerns gallium-68 compds. of formula Ch-L-B (chelate-linker-biovector), where Ch-L-Bq ($p = q = 2-5$). Ch is chosen from frameworks DOTA, NOTA, DOGA, PCDA and their derivs. having the general formula I (where M-M1-M2 form azamacrocycles N-(un)substituted with a variety of carboxymethyl groups which may be linked to biovectors (enzymes, cell surface receptors, folate, etc.).). The invention also concerns methods for obtaining such compds. by selecting metal capable of selecting such compds. for chemical synthesis thereof and their diagnostic applications, in particular in PET, PET/MRI, PET/CT imaging.
 IT 306776-78-3P 306776-79-4P
 RU: ROC (Patent); EPN (Synthetic preparation); PREP (Preparation); PACT (Reaction or reagent);
 (Preparation of gallium complexes of N-(carboxymethyl)azamacrocycles linked to biovectors as PET imaging agents)
 RN 306776-78-3 HCAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, a-[3-oxo-3-(phenylmethoxypropyl)-, 1,4,7,10-tetrakis(1,1-dimethylethyl) ester (CA INDEX NAME)

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 306776-79-4 HCAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, a-[2-carboxyethyl]-, 1,4,7,10-tetrakis(1,1-dimethylethyl) ester (CA INDEX NAME)




AB Somatostatin analogs labeled with radionuclides are of considerable interest in the diagnosis and therapy of SSTR-expressing tumors, such as gastrointestinal, small cell lung, breast and frequently nervous system tumors. In view of the favorable phys. characteristics of the Ga isotopes 67Ga and 68Ga enabling conventional tumor scintigraphy, PET and positron emission tomography, we have developed a new class of Ga-labeled somatostatin analog suitable for targeting SSTR-expressing tumors. For this purpose, 3 somatostatin analogs, OC, JOC and TATE were conjugated to the metal chelator DOTA and labeled with the radionuclides 111In, 90Y and 67Ga. They were then evaluated for their performance in the AR4-2J pancreatic carcinoma cell line, SSTR affinity, internalization/internalization in isolated cells and biodistribution in tumor-bearing nude mice. Surprisingly, we found that, compared to 111In or 90Y labeling with 67Ga considerably improved the biol. performances of the tested somatostatin analogs with respect to SSTR affinity and tissue distribution. We also found that DOTA-somatostatin analogs are rapidly taken up from non-target tissues, leading to excellent tumor-to-nontarget tissue uptake ratios. Of interest for radiotherapeutic application, [67Ga]DOTATOC was strongly internalized by AR4-2J cells. Furthermore, our results suggest a link between the radioligand charge and its kidney retention. The high selectivity of Ga-DOTA somatostatin analogs together with the different applications of Ga in nuclear oncol. suggests that Ga-DOTA somatostatin analog will become an important tool in the management of SSTR-pos. tumors.
 IT 405263-91-4D, indium-111 complex
 RU: DOTA (Diagnostic use); DOTA (Pharmacokinetics); THU (Therapeutic use);
 BIO: (Biological activity); USGS (Uses);
 (67Ga vs. 111In) and 90Y-labeled DOTA-somatostatin analogs for neuroendocrine tumor targeting)
 RN 405263-91-4 HCAPLUS
 CN L-Threonine-N-(4-carboxy-1-oxo-4-|4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecyl-|y)bucyl|-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-isopropyl-L-threonyl-L-cysteinyl-, cyclic (2+)-disulfide (9c) (CA INDEX NAME)

L14 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


PAGE 2-A




IT 405263-90-3P 405263-91-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of DOTA type azamacrocyclic prochelators for preparation of radiometal labeled mols. having improved biol. properties)

RN 405263-90-3 HCAPLUS
CN L-Cysteinamide, N-(4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl)-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl-, cyclic (2+7)-disulfide (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE I-A





PAGE 2-A




IT 306776-79-4P 405263-89-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of DOTA type azamacrocyclic prochelators for preparation of radiometal labeled mols. having improved biol. properties)

RN 306776-79-4 HCAPLUS
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, α -(2-carboxyethyl)-, 1,4,7,10-tetrakis(1,1-dimethylethyl) ester (CA INDEX NAME)

PAGE 2-A



RN 405263-89-0 HCAPLUS
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[1-(carboxymethyl)-2-(1,1-dimethylethoxy)-2-oxoethyl]-, 1,4,7-tris(1,1-dimethylethyl) ester (CA INDEX NAME)



TI A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiolabeling

AU Deisenhofer, K.-P., Powell, P., Macke, H. R.

CS Department of Radiology, Institute of Nuclear Medicine, Division of Radiological Chemistry, University Hospital, Basel, CH-4031, Switz.

SO Biorganic & Medicinal Chemistry Letters (2000), 10(18), 2133-2135

CN EML8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

OS CASREACT 133:350200


AB New DOTA-based bifunctional prochelators, e.g., 1-(1-carboxy-3-carbo-tert-butylpropyl)-10-(carbo-tert-butoxycarbonyl)-1,4,7,10-tetraazacyclododecane (DOTA(G(Bu)₂)). (I) for a broad application in the modification of biomols. with metal ions were prepared. The five-step synthesis of I has an overall yield of about 20%. The coupling of I to a bioactive peptide on solid-phase was exemplified with use of a CCK-B (cholecystokinin) analog.

IT 306776-79-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bifunctional prochelators for coupling to bioactive peptides for radiolabeling)

RN 306776-79-3 HCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, α -(3-oxo-3-(phenylmethoxy)propyl)-, 1,4,7,10-tetrakis(1,1-dimethylethyl) ester (CA INDEX NAME)




IT 306776-79-4P 306776-80-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of bifunctional prochelators for coupling to bioactive peptides for radiolabeling)

RN 306776-79-4 HCAPLUS


CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, α -(2-carboxyethyl)-, 1,4,7,10-tetrakis(1,1-dimethylethyl) ester (CA INDEX NAME)




L14 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN L-Phenylalaninamide, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecyl]butyl]-D- α -aspartyl-L-tyrosyl-L-norleucylglycyl-L-tryptophyl-L-norleucyl-L- α -aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10 / 533906

=> d bib abs hitstr l28 tot

L28 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 1999:736515 HCAPLUS
 DN 131:351678
 TI Preparation of peptide derivatives for the imaging of angiogenic disorders
 IN Puri, Rakesh; Mulvaney, Edward; Scott, Harris; Thomas D.; Remainay, Stuart
 J.; Lau, Shuang; Singh, Prabhat R.
 PA DuPont Pharmaceuticals Company, USA
 SO PCT Int. Appl., 213 pp.
 CODEN: PIXXD2
 DP Patent
 LA English
 FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO-----9958162	A2	19991118	1999WO-00006826	19990329 <-
WO-----9958162	A3	20000406		
AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, ZA, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA-----20004559	A1	19991118	1999CA-002324555	19990329 <-
AU-----9955417	A	19991129	1999AU-00005417	19990329 <-
EP-----1068224	A2	20010117	1999EP-000941944	19990329
EP-----1068224	B1	20050531		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, AU, LT, LV, FI, RO				
HU-----2001001468	A2	20010282	2001HU-000001468	19990329
BR-----9909420	A	20010295	1999BR-000009420	19990329
JP-----2002514611	I	20020521	2000JP-000548013	19990329
EE-----200005074	A	20021015	2000EE-000005074	19990329
AT-----9955469	T	20020515	1999AT-000041944	19990329
ES-----2241313	I2	20020106	1999ES-000941944	19990329
US-----6322770	A1	20011127	1999US-000281207	19990330
US-----20020015600	A1	20020207	1999US-000281209	19990330
US-----6524553	B2	20030225		
US-----9909420	B1	20030225	1999US-0000281050	19990330
ZA-----2000004286	A	20020821	2000ZA-000004286	20000821
IN-----2000NGN00342	A	20070420	2000IN-MN0000342	20000830
NO-----2000004917	A	20010100	2000ND-000004917	20000929
MK-----2000PA09574	A	20010405	2000MK-PA009574	20000929
US-----6322770	A1	20020103	2002US-000269252	20020101
US-----20030149262	A3	20030607	2002US-000396054	20020326

PRAI 1999US-00080150P P 19980331
 1999US-00112715P P 19980218
 1999US-00112732P P 19980218
 1999US-00112739P P 19980218
 1999US-00112821P P 19980218
 1999US-050006826 W 19990329
 1999US-000281050 A3 19990330
 1999US-000281209 A3 19990330
 OS Metal chelator Q is a peptide, d=1-10, Ln is a linking group, Ch is a metal-binding unit) were prepared for use in the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compds. useful for monitoring therapeutic angiogenesis treatment and destruction of angiogenesis vascularization. Thus, a cyclic [Arg-Gly-Asp-D-Tyr(N-12-|||S-[carbonyl-2-pyridinyl]hydrazono)methyl]benzenesulfonic acid (peptides) was prepared by acylation of cyclo[Arg-Gly-Asp-D-Tyr(3-aminoxypropyl)-Val] with 2-|||S-[2,5-dioxo-1-pyridinyl]-2-oxycyclopentyl-1-pyridinylhydrazono)methyl]benzenesulfonic acid (peptides) and converted into radiopharmaceutical 99mTc(VnA) (tricisine)(phosphine), where VnA represents the vitronectin receptor antagonist.


AB Compds. (Q-d-Ln-Ch (Q is a peptide, d=1-10, Ln is a linking group, Ch is a metal-binding unit) were prepared for use in the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compds. useful for monitoring therapeutic angiogenesis treatment and destruction of angiogenesis vascularization. Thus, a cyclic [Arg-Gly-Asp-D-Tyr(N-12-|||S-[carbonyl-2-pyridinyl]hydrazono)methyl]benzenesulfonic acid (peptides) was prepared by acylation of cyclo[Arg-Gly-Asp-D-Tyr(3-aminoxypropyl)-Val] with 2-|||S-[2,5-dioxo-1-pyridinyl]-2-oxycyclopentyl-1-pyridinylhydrazono)methyl]benzenesulfonic acid (peptides) and converted into radiopharmaceutical 99mTc(VnA) (tricisine)(phosphine), where VnA represents the vitronectin receptor antagonist.

IT 192635-89-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PACT (Reactant or reagent); (Preparation of peptide derivs. for the imaging of angiogenic disorders)

RN 192635-89-5 HCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetracetic acid, 1,7,10-tris(1,1-dimethyl ethyl) 4-(phenylmethyl) ester (CA INDEX NAME)

L28 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




L28 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
 AN 1999:442438 HCAPLUS
 DN 131:239827
 TI Radiometal-labelled macrocyclic chelator-derivatized somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy
 AU Heppeler, A.; Froidevaux, S.; Macke, H. R.; Jermann, E.; Behe, M.; Powell, P.; Henning, M.
 CS Institute of Nuclear Medicine, Div. of Radiological Chemistry, University Hospital Basel, Basel, 4031, Switz.
 SO Chem.-A. Eng. Journal (1999), 5(7), 1974-1981
 CODEN CEUDJD; ISSN: 0947-6359
 PB Wiley-VCH Verlag GmbH
 DT Journal
 LA English
 AB A new radioactive DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracatic acid) prochelator (4,7,10-tricarboxymethyl-tert-Bu ester 1,4,7,10-tetraazacyclododecane-1-acetate) was synthesized which is useful in solid-phase and solution-phase peptide synthesis; it was coupled to the somatostatin analog DOTA-lys5(BOC)-octreotide. Deprotection in one step afforded the DOTA-lys5(BOC)-octreotide (DOTA-OCT). This peptide, modified with a chelator, was complexed with the radiometals $^{67}\text{Ga}^{3+}$, $^{111}\text{In}^{3+}$ and $^{90}\text{Y}^{3+}$ in high yields and with high specific activities. The three radiopeptides show high stability in human serum and high affinity to the somatostatin receptor; it is four to five times higher than $^{67}\text{Ga}^{3+}$ compared to the standard DOTA-OCT. The $^{67}\text{Ga}^{3+}$ -DOTA compound also shows significantly higher tumor-to-liver kidney uptake than the two congeners. $^{67}\text{Ga}^{3+}$ -DOTA(OCT) was compared in patients with the com. available gold standard $^{111}\text{In}^{3+}$ -DTPAO-D-Phe-octreotide. The new compound delineates SRIF-receptor pos. tumors very favorably and shows distinctly lower uptake in the kidney. Evidence that the separation of the coordination channel of the metal causes the differences in the biol. behavior. Indeed, a crystallog. study of the Ga^{3+} and Y^{3+} complexes of the model peptide DOTA-D-PheNH₂ showed differences in the geometry of the complexes. The gallium complex is hexacoordinated with pseudooctahedral cis geometry and a folded macrocyclic unit. The equatorial plane is formed by two transaxial nitrogen atoms of the cycles and two oxygens of the corresponding carboxylate groups. The two axial positions are formed by the two remaining ring nitrogen atoms. The amide carboxyl oxygen is not bound to the metal and one carboxylate group is free and most likely contributes to the tetrahedral coordination. Evidence that the separation of the coordination channel of the metal causes the differences in the biol. behavior. In contrast, the structure of Y-DOTA-D-PheNH₂ has a trigonal bipyramidal coordination, and includes the amide carboxyl oxygen. The geometry is a compact and somewhat distorted square-antiprism with two almost perfect planes ($\text{N}4$ and $\text{O}4$) with a maximum deviation of 0.025 Å. The dihedral angle between the two planes is only 0.36°.

IT 192635-89-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PACT (Reactant or reagent); (radiometal-labelled macrocyclic chelator-derivatized somatostatin analogue with tumour-targeting properties)

RN 192635-89-5 HCAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetracatic acid, 1,7,10-tris(1,1-dimethyl ethyl) 4-(phenylmethyl) ester (CA INDEX NAME)



RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> b uspatall
FILE 'USPATFULL' ENTERED AT 16:30:23 ON 10 JUN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 16:30:23 ON 10 JUN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:30:23 ON 10 JUN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr 129 tot


L29 ANSWER 1 OF 2 USPATFULL on STN
 AN 2007:288696 USPATFULL
 II PRESSURE TANK FITTING ASSEMBLY
 IN Cress, Richard J., Indianapolis, IN, UNITED STATES
 Patey, Rich D., Indianapolis, IN, UNITED STATES
 Carter, Jeffrey M., Anderson, IN, UNITED STATES
 PI US-20070252386 A1 20071101
 AI 2006US-000533906 A1 20060921 (11)
 PPAI 2005US-000719364R 20050922 (60)
 2005US-000785103B 20060323 (60)
 DT Utility
 FS Application
 LREP BOSE MCKINNEY & EVANS LLP, JAMES COLES, 135 N PENNSYLVANIA ST, SUITE 2700, INDIANAPOLIS, IN, 46204, US
 CIRW Number of Claims: 31
 ECL Examiner: J. L. D.
 DRWN 12 Drawing Page(s)
 LN.CNT 581
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

A fitting assembly for use with a component, such as a tank containing a fluid. The fitting assembly can be used with a pressurized tank coupled to a pressurized fluid system, including pressurized air. The fitting assembly includes a spud and a corresponding fitting wherein the spud or fitting include pins which cooperate with a corresponding groove or slot of the related spud or fitting.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 306776-78-3P 405263-88-9P
 (intermediate product in preparation of DOTA type azamacrocyclic prochelator and labeling with 90Tc)


RN 306776-80-7 USPATFULL
 CN 1-phenylalaninamide, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid, α-[3-oxo-3-(phenylmethoxy)propyl]-, 1,4,7,10-tetrakis(1,3-dimethylethyl) ester (CA INDEX NAME)



RN 405263-88-9 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, 10-[l-[(1,1-dimethylethoxy)carbonyl]-3-oxo-3-(phenylmethoxy)propyl]-, 1,4,7-tris(1,1-dimethylethyl) ester (CA INDEX NAME)


L29 ANSWER 1 OF 2 USPATFULL on STN (Continued)

PAGE 1-B




IT 405263-90-3DP, radiometal complexes 405263-91-4DP,
 radiometal complexes
 (prepared from DOTA type azamacrocyclic prochelators as radiometal labeled mol. having improved biol. properties for diagnostic or therapeutic use)

RN 405263-90-3 USPATFULL
 CN L-Cysteaminide, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2S)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2+7)-disulfide (SCl) (CA INDEX NAME)



PAGE 1-A

L29 ANSWER 1 OF 2 USPATFULL on STN (Continued)




IT 306776-80-7P
 (preparation from DOTA type azamacrocyclic prochelator and labeling with 90Tc)

RN 306776-80-7 USPATFULL
 CN 1-phenylalaninamide, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-D-α-aspartyl-L-tyrosyl-L-norleucylglycyl-L-tryptophyl-L-norleucyl-L-α-aspartyl- (9Cl) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L29 ANSWER 1 OF 2 USPATFULL on STN (Continued)


PAGE 2-A



RN 405263-91-4 USPATFULL
 CN L-Threonine, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2S)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2+7)-disulfide (SCl) (CA INDEX NAME)




PAGE 1-A



IT 405263-90-3P 405263-91-4P
 (preparation from DOTA type azamacrocyclic prochelators for preparation of radiometal labeled mol. having improved biol. properties)

RN 405263-90-3 USPATFULL
 CN L-Cysteaminide, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2S)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2+7)-disulfide (SCl) (CA INDEX NAME)

L29 ANSWER 2 OF 2 USPATFULL on STN (Continued)

IT 306776-60-7P (preparation from DOTA type azamacrocyclic prochelator and labeling with ^{90}Y)


RN 306776-80-7 USPATFULL

CN L-Phenylalaninamide, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-D- α -aspartyl-L-tyrosyl-L-norleucylglycyl-L-tryptophyl-L-norleucyl-L- α -aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L29 ANSWER 2 OF 2 USPATFULL on STN (Continued)

PAGE 1-B


IT 405263-90-3D β radionuclide complexes 405263-91-4D β

(preparation from DOTA type azamacrocyclic prochelators as radiometal labeled mol. having improved biol. properties for diagnostic or therapeutic use)


RN 405263-90-3 USPATFULL

CN L-Cysteine, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl-, cyclic (2+7)-disulfide (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-A




L29 ANSWER 2 OF 2 USPATFULL on STN (Continued)

L29 ANSWER 2 OF 2 USPATFULL on STN (Continued)



PAGE 1-A

RN 405263-91-4 USPATFULL
CN L-Threonine, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic (2+7)-disulfide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


RN 405263-91-4 USPATFULL
CN L-Threonine, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl-, cyclic (2+7)-disulfide (9CI) (CA INDEX NAME)

IT 405263-90-3P 405263-91-4P (preparation from DOTA type azamacrocyclic prochelators for preparation of radiometal labeled mol. having improved biol. properties)

RN 405263-90-3 USPATFULL

CN L-Cysteine, N-[4-carboxy-1-oxo-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]butyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl-, cyclic (2+7)-disulfide (9CI) (CA INDEX NAME)


PAGE 2-A




IT 306776-79-4P 405263-89-0
(preparation of DOTA type azamacrocyclic prochelators for preparation of
radioactive labeled mols. having improved biol. properties)

RN 306776-79-4 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetracetic acid,
α-(2-carboxyethyl)-, 1,4,7,10-tetrakis(1,1-dimethylethyl) ester
(CA INDEX NAME)



RN 405263-89-0 USPATFULL
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[1-(carboxymethyl)-2-(1,1-dimethylethoxy)-2-oxoethyl]-, 1,4,7-tris(1,1-dimethylethyl) ester
(CA INDEX NAME)




10 / 533906

=> d bib abs hitstr 134 tot


L34 ANSWER 1 OF 13 USPAFULL on STN
 AN 2000:40666 USPAFULL
 TI Liposomal agents
 IN Gary, Martin Wayne, PA, United States
 Veradrian, John Wayne, PA, United States
 Watson, Alan David, Wayne, PA, United States
 Nycomed Salutar, Inc., Wayne, PA, United States (U.S. corporation)
 PI US-----6045821 20000404 <--
 AI 1997US-000809729 19970529 (8) <--
 1995W0-A89002378 19951009
 19970529 RCT 371 date
 19970529 RCT 102(e) date
 PRAI 1994GB-00020390 19941010
 DE Utility
 ES Granted
 EXNAM Primary Examiner: Mishore, Gollamudi S.
 LREP Bacon & Thomas
 CLMN Number of Claims: 16
 ECL Exemplary Claim: 1
 DRBN No Drawings
 LN.CNT 1316
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a liposomal agent comprising liposomes having bound to a membrane thereof, a metal chelating agent comprising a macrocyclic chelate moiety which, attached to a single ring atom thereof, a lipophilic membrane associating moiety.
 The preparation and reaction; chelate-containing liposomal agents, and their preparation, for diagnostic imaging and therapeutic use)

RN 173308-18-4 USPAFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetracetic acid,
 tris(1-dimethyl ethyl) methyl ester (9CI) (CA INDEX NAME)



L34 ANSWER 2 OF 13 USPAFULL on STN (Continued)



L34 ANSWER 2 OF 13 USPAFULL on STN
 AN 1999:132199 USPAFULL
 TI Dichelants
 IN Campbell, Michael, Mountain View, CA, United States
 Watson, Alan D., Campbell, CA, United States
 Fellmann, Jere D., Livermore, CA, United States
 Koo, Michael, San Jose, CA, United States
 Nycomed Salutar, Inc., Wayne, PA, United States (U.S. corporation)
 PI US-----5972307 19990264 <--
 AI 1997US-000809729 19970529 (8) <--
 RLI Division of Ser. No. 1994US-000226760, filed on 12 Apr 1994, now patented, Pat. No. US-----5650133 which is a continuation-in-part of Ser. No. 1993US-000086996, filed on 7 Jul 1993, now patented, Pat. No. US-----5446145 which is a continuation-in-part of Ser. No. 1990US-000086907, filed on 19 Jul 1990, now patented, Pat. No. US-----5281704, said Ser. No. US 226760 which is a continuation-in-part of Ser. No. 1992US-000885028, filed on 12 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 468107

PRAI 1993GB-00020277 19931001
 DT Utility
 ES Granted
 EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Hartley, Michael G.

LREP Fisher Richardson P.C.
 CLMN Number of Claims: 5
 ECL Exemplary Claim: 1
 DRBN No Drawings
 LN.CNT 1802
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to chelating agents, in particular compounds having two macrocyclic chelate groups linked by a bridge containing an ester or amide bond, especially compounds of formula Vb #5TR1# (wherein each X which may be the same or different is NZ, O or S, at least two Xs being NZ;

each Z is a group R.sup.1 or a group CR.sup.1.sub.2 Y, at least one Z, and preferably 2 or 3 Zs, on each macrocyclic ring being a group CR.sup.1.sub.2 Y;

each Y is a group CO.sub.2 H, PO.sub.2.3 H, SO.sub.2.3 H, CONR.sup.1.sub.2, CON(OR.sup.1)R.sup.1, CNS or CONR.sup.1 NR.sup.1.sub.2, preferably COOH;

m is 0 or 1 or 2, preferably 1; each n is 2 or 3, preferably 2; q is 1 or 2, preferably 1;

each R.sup.1 which may be the same or different is a hydrogen atom or an alkyl group optionally substituted by one or more hydroxy and/or alkoxy groups;

and D is a bridging group having a molecular weight of less than 1000, preferably less than 500, joining two macrocyclic rings via at least one amide or ester bond) and salts and metal chelates thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 137076-50-7P
 (Preparation of a polychelant chelating agent preparation)
 RN 137076-50-7 USPAFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetracetic acid, tetraethyl ester (9CI) (CA INDEX NAME)

L34 ANSWER 3 OF 13 USPAFULL on STN
 AN 1999:75290 USPAFULL
 TI Polyaminated ligands and metal complexes thereof
 IN Meyer, Dominique, Saint-Maur, France
 Roche, Daniel, Obernai, Seulles, France
 Schaefer, Jean-christian, France
 Simonot, Christian, Paris, France
 Guerbet, S.A., Villepinte, France (non-U.S. corporation)
 PI US-----5919432 19990706 <--
 AI 1997US-000086983 19970228 (8) <--
 RLI Division of Ser. No. 1994US-000086982, filed on 28 Feb 1997, now patented, Pat. No. US-----5712389 which is a continuation of Ser. No. 1994US-000366732, filed on 30 Dec 1994, now abandoned


PRAI 1993FR-00015933 19931230
 DT Utility
 ES Granted
 EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Srivada, Pavaraman K.

LREP Jacobson, Price, Holman & Stern PLLC
 CLMN Number of Claims: 10
 ECL Exemplary Claim: 1
 DRBN No Drawings
 LN.CNT 945
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polyaminocarboxylic acid derivatives, which are chelating agents of paramagnetic metal ions, in which at least 3 of the donor nitrogen atoms carry identical or different substituents, of formula

CH(R.sub.1)-X
 In which X represents CO.sub.2 R.sub.2 R.sub.3, CONR.sub.2.b R.sub.2.c or PR.sub.2.dIO.R.sub.2.b H and R.sub.2.a, R.sub.2.b and R.sub.2.c, which are identical or different, represent H or optionally hydroxylated (C.sub.1-C.sub.8)alkyl, R.sub.2.d represents OH, (C.sub.1-C.sub.8)alkyl or (C.sub.1-C.sub.8)alkoxy and R.sub.2.b represents a hydrophilic group with a molecular weight greater than 200 containing at least 3 oxygen atoms, with the proviso that at least 3 of the X groups are optionally sulfidized acid functional groups.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 167272-14-2
 (for preparation of paramagnetic metal complexes as NMR imaging agents)
 RN 167272-14-2 USPAFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetracetic acid,
 o,o',o'',o'''-tetrakis(3-aminopropyl)-,
 tetrakis(1-methylethyl) ester, tetrahydrochloride (9CI) (CA INDEX NAME)




●4 HCl

IT 167272-21-1P 167272-22-2P
 (for preparation of tetraazacyclododecane derivative complexes with paramagnetic metal ions as NMR imaging agents)
 RN 167272-21-1 USPAFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,

L34 ANSWER 3 OF 13 USPATFULL on STN (Continued)
 $\alpha,\alpha',\alpha'',\alpha''''$ -tetraakis[3-(1,3-dihydro-1,3-dioxo-2H-isocindol-2-yl)propyl]-, tetrakis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 167272-22-2 USPATFULL
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrabutanoic acid,
 $\gamma,\gamma',\gamma'',\gamma'''$ -tetraakis(methoxycarbonyl)-,
tetramethyl ester (9CI) (CA INDEX NAME)




IT 167272-23-LDP gadolinium complexes
(preparation as NMR imaging agents)
RN 167272-21-1 USPATFULL
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
 $\alpha,\alpha',\alpha'',\alpha''''$ -tetraakis[3-(1,3-dihydro-1,3-dioxo-2H-isocindol-2-yl)propyl]-, tetrakis(1-methylethyl) ester (9CI) (CA INDEX NAME)

L34 ANSWER 3 OF 13 USPATFULL on STN (Continued)



RN 167272-22-2 USPATFULL
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrabutanoic acid,
 $\gamma,\gamma',\gamma'',\gamma'''$ -tetraakis(methoxycarbonyl)-,
tetramethyl ester (9CI) (CA INDEX NAME)




IT 167272-23-LDP gadolinium complexes
(preparation as NMR imaging agents)
RN 167272-21-1 USPATFULL
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
 $\alpha,\alpha',\alpha'',\alpha''''$ -tetraakis[3-(1,3-dihydro-1,3-dioxo-2H-isocindol-2-yl)propyl]-, tetrakis(1-methylethyl) ester (9CI) (CA INDEX NAME)

L34 ANSWER 4 OF 13 USPATFULL on STN
AN 1999:37270 USPATFULL
TI Metal complexes of polyamino oxides, and their utilization in diagnostic imaging
IN Moyer, Dominique, Saint Malo, France
Pereira, Olivier, Senlis, France
Schaefer, Michel, Lagny, France
Simonot, Christian, Paris, France
PA Guerbet S.A., Villepinte, France (non-U.S. corporation)
PI US-----5884020 19990323 <--
WO-----00091359 19970116 <--
AI 1997US0-000981022 19971229 (8)
1996W0-FR0000992 19960625
1997US0-000992 19971229 PCT 371 date
1997US0-000992 19971229 PCT 102(e) date
PRAI 1995FR-000007860 19950629
DT Utility
FS Granted
EXNM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Jones, Dameron
LREP Jacobson, Price, Holman & Stern, PLLC
CLM Number of Claims: 7
ECL Evidentiary Claim: 1
DRMN No Drawings
LN,CNT 420
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns gadolinium complexes of formula: ##STR3## in which R represents a group of formula: ##STR3## in which X is Br or I; R'.sub.1 is H or optionally hydroxylated alkyl; R'.sub.2 is hydroxylated alkyl; or alternatively R'.sub.1 is H and R'.sub.2 is a group of formula: ##STR3## X being as defined above, and R'.sub.1 and R'.sub.2 being as defined for R'.sub.1 and R'.sub.2 excepted that they do not represent A, provided that --CO--NR'.sub.1 R'.sub.2 or --CO--NR'.sub.1 R'.sub.2 comprises at least 2 hydroxyl groups, and M represents H or the cation of an inorganic or organic base.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 167272-22-2P (for preparation of gadolinium tetraazamacrocyclic poly(amino acid) complexes as MRI contrast agents)

RN 167272-22-2 USPATFULL
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrabutanoic acid,
 $\gamma,\gamma',\gamma'',\gamma'''$ -tetraakis(methoxycarbonyl)-,
tetramethyl ester (9CI) (CA INDEX NAME)



L34 ANSWER 5 OF 13 USPATFULL on STN
AN 1998:138472 USPATFULL
TI Dendrimeric compounds
IN Margerum, Larry, Wayne, PA, United States
Camerson, Brian, Bel Air, CA, United States
Feldman, Jerry, Dallas, Livermore, CA, United States
Garity, Martha, San Clemente, CA, United States
Nycomed Salutar, Inc., Wayne, PA, United States (U.S. corporation)
PA US-----5834020 19981110 <--
WO-----9528966 19951107 <--
AI 1997US0-000722082 19970121 (8)
1995W0-GD0000898 19950420
19970123 19970121 PCT 371 date
19970123 19970121 PCT 102(e) date
PRAI 1994GB-000007812 19940420
DT Utility
FS Granted
EXNM Primary Examiner: Levy, Neil S.
LREP Fish & Richardson P.C.
CLM Number of Claims: 17
ECL Evidentiary Claim: 1
DRMN No Drawings
LN,CNT 2049
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a dendrimeric compound comprising a dendrimeric core having a plurality of diametrically or therapeutically active moieties characterized in that the molecular skeleton of said compound contains at least one biodegradable cleavage site such that on cleavage thereof said active moieties are released in renally excretable form.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 173308-18-4P (preparation of gadolinium complexes as contrast agents)
RN 173308-18-4 USPATFULL
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetracetic acid,
tris(1,1-dimethylethyl) methyl ester (9CI) (CA INDEX NAME)



L34 ANSWER 6 OF 13 USPATFULL on STN

AN 1998:9610 USPATFULL

TI Polyaminated ligands and metal complexes thereof
IN Meyer, Dominique, Saint-Maur, France
Poujol, Odile, Senlis, France
Schaefer, Michel, Lagny, France

Simonot, Christian, Paris, France

PA Guerbet, S.A., Villepinte, France (non-U.S. corporation)

PI US55712389 19980127 <--

AI 1997US00015933 19970226 (8)

RLI Continuation-of Ser. No. 1994US-000366732, filed on 30 Dec 1994, now abandoned

PRAT 1993FP-000015933 19931230

DT Utility

FS Granted

EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Sripada,

Pavanaram K.

LREP Jacobson, Price, Holman & Stern, PLLC

CLMN Number of Claims: 18

BCI 1 Independent Claim: 1

DRDN No Drawings

LN.CNT 1035

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Poly(amino acid) derivatives, which are chelating agents of paramagnetic metal ions, in which at least 3 of the donor nitrogen atoms carry identical or different substituents, of formula

CH (R_{sub}1) --X-in which X represents C_{sub}1-R_{sub}2-R_{sub}3, C_{sub}2-R_{sub}2-R_{sub}3 or P(R_{sub}4-O_{sub}2-R_{sub}5)H and R_{sub}2, R_{sub}3 and R_{sub}4, which are identical or different, represent H or optionally hydroxylated (C_{sub}1-C_{sub}2)-alkyl, R_{sub}2, R_{sub}3 represents OH, (C_{sub}1-C_{sub}2)-alkyl or (C_{sub}1-C_{sub}2)-alkoxy and R_{sub}4 represents a hydrophilic group with a molecular weight greater than 200 containing at least 3 oxygen atoms, with the proviso that at least 3 of the X groups are optionally sulfidized acid functional groups.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 167272-14-2 USPATFULL (preparation of paramagnetic metal complexes as NMR imaging agents)


RN 167272-14-2 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, $\alpha,\alpha',\alpha'',\alpha'''$ -tetraakis(3-amino propyl)-, tetrakis(1-methylethyl) ester, tetrahydrochloride (9CI) (CA INDEX NAME)


● 4 HCl

IT 167272-21-1P 167272-22-2P
(For preparation of tetraazacyclododecane derivative complexes with paramagnetic


L34 ANSWER 6 OF 13 USPATFULL on STN (Continued)

L34 ANSWER 6 OF 13 USPATFULL on STN (Continued)
metal ions as NMR imaging agents)

RN 167272-21-1 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, $\alpha,\alpha',\alpha'',\alpha'''$ -tetraakis(3-(1,3-dihydro-1,3-dioxo-2H-isooindol-2-yl)propyl)-, tetrakis(1-methylethyl) ester (9CI) (CA INDEX NAME)

RN 167272-22-2 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, $\gamma,\gamma',\gamma'',\gamma'''$ -tetraakis(methoxypropionyl)-, tetracarboxylic ester (9CI) (CA INDEX NAME)

IT 167272-21-1DP, gadolinium complexes

(preparation as NMR imaging agents)

RN 167272-21-1 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, $\alpha,\alpha',\alpha'',\alpha'''$ -tetraakis(3-(1,3-dihydro-1,3-dioxo-2H-isooindol-2-yl)propyl)-, tetrakis(1-methylethyl) ester (9CI) (CA INDEX NAME)

L34 ANSWER 7 OF 13 USPATFULL on STN (Continued)

L34 ANSWER 7 OF 13 USPATFULL on STN

AN 97:96997 USPATFULL

TI Linear oligomeric polychelant compounds

IN Love, David B., Wayne, PA, United States

Love, William J., Wayne, PA, United States

Himelshaus, Richard J., Wayne, PA, United States

Watson, Alan D., Wayne, PA, United States

Rocklage, Scott M., Wayne, PA, United States

Salutar, Inc., Sunnyvale, CA, United States (U.S. corporation)

PA US55712389 19980127 <--

PT 1997US00015933 19970226 (8)

AI Continuation-in-part of Ser. No. 1993US-000086996, filed on 7 Jul 1993,

now patented, Pat. No. US-----546146 which is a division of Ser. No.

1990US-000468107, filed on 19 Jan 1990, now patented, Pat. No.

US-----5281704

DT Utility

FS Granted

EXNAM Primary Examiner: Gupta, Yogendra N.

LREP Fish & Richardson PC

CLMN Number of Claims: 12

BCI 1 Independent Claim: 1

DRDN No Drawings

LN.CNT 1846

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Linear oligomeric polychelant compounds and chelates formed therewith have alternating chelating and bridging units bound together by amide or ester linkages. The compounds have between 3 and 100 chelant moieties, at least one of which complexes a paramagnetic metal ion. The polychelants and especially their paramagnetic metal polychelates are particularly suitable for diagnostic imaging.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 137076-50-7P (preparation of linear oligomeric polychelant polyaminocarboxylic acids and their paramagnetic metal chelates for diagnostic imaging)

RN 137076-50-7 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tetraethyl ester (9CI) (CA INDEX NAME)




L34 ANSWER 8 OF 13 USPATFULL on STN
 AN 96:94691 USPATFULL
 TI Triazole macrocycles
 IN Parker, David J., Durham, United Kingdom
 Baker, Nigel R. A., Thame, United Kingdom
 Milligan, Thomas J., Maidenhead, United Kingdom
 PA Celitron Therapeutics Limited, Slough, United Kingdom (non-U.S. corporation)
 PI US 5,046,565 19861015 <--
 AI 1995US0-000467913 19950606 (8)
 RLI Continuation of Ser. No. 1992US-000948508, filed on 18 Sep 1992, now abandoned which is a division of Ser. No. 1992US-000817999, filed on 9 Jan 1992, now abandoned which is a continuation of Ser. No. 1990US-000601700, filed on 30 Oct 1990, now abandoned
 PRAI 1988US0-000003024 19890210
 1988US0-000003025 19890210
 DT Utility
 FS Granted
 EXAM Primary Examiner: Detlow, Philip I.
 LREP Newell, G. & Bridge, Collins
 CLMN Number of Claims: 10
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 570
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Triazole macrocycles carrying a --CH₂.sub.2 COOH, --CH₂.sub.2 CONR.sup.6 R.sup.7, --CH₂.sub.2 P(R.sup.5).sub.2 H, or --CH₂.sub.2 PO₂.sub.3 H.sub.2 group on two of the three ring nitrogen atoms and a --CH(L--Z)COOH, --CH(L--Z)CONR.sup.6 R.sup.7, --CH(L--Z)P(R.sup.5).sub.2 H, or --CH(L--Z)PO₂.sub.3 H.sup.2 group on the third ring nitrogen atoms, in which L is an amine linking radical and Z is any group capable of reacting with a thiol, amino, carboxy, hydroxyl, aldehyde, aromatic, or heteroaromatic group, and metal complexes thereof, are useful for imaging, diagnosis, and therapy. A typical embodiment is N-[5-carboxy-5-(4,7-bis-(carboxymethyl)-1,4,7-triazaacyclonon-1-yl)pentyl] 3-maleimidopropionamide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 132262-07-8P (preparation of for imaging and treatment of tumor)
 RN 132262-07-8 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, α-[4-(benzoylamino)butyl]-, tetraethyl ester (9CI) (CA INDEX NAME)




L34 ANSWER 10 OF 13 USPATFULL on STN
 AN 94:93084 USPATFULL
 TI Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents
 IN Desreux, Jean F., Angleur, Belgium
 Tweedie, Michael F., Princeton, NJ, United States
 Ratner, Alan C., Hamilton, New Jersey, United States
 Wagner, Thomas R., Princeton, NJ, United States
 Marinelli, Edmund R., Lawrenceville, NJ, United States
 Bristol-Myers Squibb, Princeton, NJ, United States (U.S. corporation)
 PI US 5,358704 19941025 <--
 AI 1993US0-000129870 19930930 (8)
 DT Utility
 FS Granted
 EXAM Primary Examiner: Hollinden, Gary E.
 LREP Kilcoyne, John M.
 CLMN Number of Claims: 20
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 841
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds of the formula #STR1# and metal chelates of the compounds are useful particularly for MRI of the hepatobiliary system.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 160113-00-8P (preparation of tetraazamacrocyclic chelates for magnetic resonance contrast agents for hepatobiliary system)
 RN 160113-00-8 USPATFULL
 CN Dibenzo[b,h][1,4,7,10]tetraazacyclododecene-5,8,13,16-tetrasacetic acid, hexadecahydro-, tetrakis[2-oxo-2-(phenylmethoxy)ethyl] ester, (4aR*,6aS*,12aS*,16aR*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 136582-74-6P (preparation and deprotection of)
 RN 136582-74-6 USPATFULL
 CN 13-Oxa-3,6,9,15-tetraazacyclo[9.3.1]pentadecane-3,6,9,15-tetrasacetic acid, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




L34 ANSWER 12 OF 13 USPATFULL on STN
 AN 94:7797 USPATFULL
 II Polychelant compounds
 IN Love, David P., Campbell, CA, United States
 Dow, William C., Fremont, CA, United States
 Himmelbach, Richard J., Pleasanton, CA, United States
 Watson, Alan D., Campbell, CA, United States
 Rocklage, Scott M., Los Gatos, CA, United States
 Salutor, Inc., Sunnyvale, CA, United States (U.S. corporation)
 PA US 6,128,1704 19990125 <--
 AI 1390US-000468107 13900119 (7)
 PPAI 1989GB-000023843 19891023
 DT Utility
 FS Granted
 EXAM Examiner: Shah, Mukund J.; Assistant Examiner: Ward, E. C.
 CLMN Number of Claims: 25
 ECL Exemplary Claim: 1
 DRW No Drawings
 LN.CNT 1759
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB There are disclosed polychelant compounds, that is multi-site metal chelating agents, and chelates formed therewith. The polychelants and especially their paramagnetic metal, heavy metal or radioactive metal polychelates are particularly suitable for use in diagnostic imaging, heavy metal detection and removal. The polychelants have a linearly branched oligomeric structure comprising alternating chelant and linker moieties bound together by amide or ester moieties, each polychelant comprising at least two said chelant moieties capable of complexing a metal ion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 137076-50-7P
 (preparation of, in polychelant chelating agent preparation)
 RN 137076-50-7 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tetraethyl ester (9CI) (CA INDEX NAME)



L34 ANSWER 13 OF 13 USPATFULL on STN
 AN 91:80052 USPATFULL
 II Chelating agents
 IN Dorn, Richard T., Downingtown, PA, United States
 Debevoise, Robert W., Downingtown, PA, United States
 Centocor, Malvern, PA, United States (U.S. corporation) <--
 PA US 5,053,503 19911001
 AI 1989US-000312767 19890217 (?)
 DT Utility
 FS Granted
 EXAM Primary Examiner: Springer, David B.
 LREP Woodcock Washburn Kurtz Mackiewicz & Norris
 CLMN Number of Claims: 23
 EC1 Exemplary Claim: 1,22,23
 DRW Drawings
 LN.CNT 604
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A bifunctional chelating agent for joining an antibody or antibody fragment and a metallic radionuclide is disclosed. The agent consists of a derivative of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid or a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid or an organic linking radical which optionally contains a cleavable group, and a function capable of reacting with a site on a protein. Radiodiagnostic or radiotherapeutic precursors comprising an antibody or antibody fragment and the above-described bifunctional chelating agent and radiodiagnostic or radiotherapeutic agent comprising a metallic radionuclide and the above-mentioned precursor are also disclosed.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 1390US-00 1390US-86-2P
 (preparation of, intermediate for chelating agents-protein conjugates)
 RN 139085-84-0 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-(6-oxo-6-(phenylmethoxy)hexyl-, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 139085-86-2 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-(6-{2-[2-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)ethoxy]-6-oxohexyl}-tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

L34 ANSWER 13 OF 13 USPATFULL on STN (Continued)

PAGE 1-A



PAGE 2-A



=> d his

```
(FILE 'HOME' ENTERED AT 15:49:45 ON 10 JUN 2008)

FILE 'HCAPLUS' ENTERED AT 15:49:57 ON 10 JUN 2008
L1      1 US20060233704/PN

FILE 'REGISTRY' ENTERED AT 15:50:03 ON 10 JUN 2008
FILE 'HCAPLUS' ENTERED AT 15:50:03 ON 10 JUN 2008
L2      TRA L1 1- RN :      31 TERMS

FILE 'REGISTRY' ENTERED AT 15:50:03 ON 10 JUN 2008
L3      31 SEA L2
L4      STR
L5      5 L4
L6      599 L4 FULL
          SAV TEM L6 J906C1G1/A
L7      7 L6 AND L3
L8      STR L4
L9      7 L8 SAM SUB=L6
L10     170 L8 FULL SUB=L6
          SAV TEM J906C1G1S1/A L10
L11     4 L10 AND L3
L12     7 L7,L11
L13     166 L10 NOT L12

FILE 'HCAPLUS' ENTERED AT 16:07:59 ON 10 JUN 2008
L14     4 L12
L15     116 L13
L16     36 L15 AND PD<=20000512
L17     32 L15 AND PD<=19990512
L18     40 L15 AND (PRD<=20010511 OR AD<=20010511)
L19     36 L16-17
L20     15 L19 NOT L18
L21     36 L19-20

FILE 'HCAOLD' ENTERED AT 16:11:00 ON 10 JUN 2008
L22     0 L12
L23     0 L13

FILE 'HCAPLUS' ENTERED AT 16:15:41 ON 10 JUN 2008
L24     19 L18 NOT L21
          SEL HIT RN

FILE 'REGISTRY' ENTERED AT 16:16:12 ON 10 JUN 2008
L25     23 E1-23
L26     67 E24-90
L27     1 L26 AND C35H58N4O8

FILE 'HCAPLUS' ENTERED AT 16:25:56 ON 10 JUN 2008
L28     2 L27 AND L21

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 16:27:25 ON 10 JUN 2008
L29     2 L12
L30     100 L13
L31     13 L30 AND PD<=20000512
L32     11 L30 AND PD<=19990512
L33     72 L30 AND (PRD<=20010511 OR AD<=20010511)
L34     13 L31-32
```

=>